Literature DB >> 9120925

The International Continence Society "Benign Prostatic Hyperplasia" Study: international differences in lower urinary tract symptoms and related bother.

W P Witjes1, J J de la Rosette, J L Donovan, T J Peters, P Abrams, H E Kay, K Höfner, A C Kinn, S Walter.   

Abstract

PURPOSE: We investigated the international differences in the reporting of lower urinary tract symptoms and related bother in patients with symptoms suggestive of bladder outlet obstruction.
MATERIALS AND METHODS: Multiple logistic regression analysis was used to evaluate international differences in the reporting of lower urinary tract symptoms and related bother in 1,271 patients from 12 countries who participated in the International Continence Society "benign prostatic hyperplasia" study.
RESULTS: Country of origin was significantly associated with the prevalence of a large number of lower urinary tract symptoms (10 of 20), even after adjusting for potentially confounding variables, including physical and socio-demographic factors. Country of origin was also significantly associated with the reporting of bother but for a much smaller number of symptoms (2).
CONCLUSIONS: In different countries lower urinary tract symptoms may be reported to different extents. Therefore, the results of studies in particular countries may not be generally applicable to other countries. It is likely that symptom scores will conceal this variation, necessitating consideration of individual symptoms (as in the International Continence Society "benign prostatic hyperplasia" study) or the development of country specific scoring systems. An alternative would be to focus on bother, which appeared to be much less sensitive to international differences.

Entities:  

Mesh:

Year:  1997        PMID: 9120925     DOI: 10.1016/s0022-5347(01)64955-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Treatment of Concomitant OAB and BPH.

Authors:  Matthew C Moss; Tameem Rezan; Umar R Karaman; Alex Gomelsky
Journal:  Curr Urol Rep       Date:  2017-01       Impact factor: 3.092

2.  Efficacy of Combination Treatment with Tadalafil and Mirabegron in Patients with Benign Prostatic Hyperplasia Who Presented with Persistent Storage Symptoms After Tadalafil Monotreatment: A Prospective, Multicenter, Open-Labeled Study.

Authors:  Masashi Honda; Yusuke Kimura; Shogo Teraoka; Bunya Kawamoto; Shuichi Morizane; Katsuya Hikita; Atsushi Takenaka
Journal:  Yonago Acta Med       Date:  2022-08-04       Impact factor: 1.371

3.  Development of a quality of life scale specific for patients with benign prostatic hyperplasia.

Authors:  Kamil Cam; Talha Muezzinoglu; Omer Aydemir; Recep Buyukalpelli; Gokhan Toktas; Hakan Gemalmaz
Journal:  Int Urol Nephrol       Date:  2013-02-19       Impact factor: 2.370

Review 4.  Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia?

Authors:  Kyu-Sung Lee; Hye Won Lee; Deok Hyun Han
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

Review 5.  Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder.

Authors:  Seung Hwan Lee; Ji Youl Lee
Journal:  Prostate Int       Date:  2014-06-30

6.  Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy.

Authors:  Tong Cai; Ning Wang; Liye Liang; Zhongbao Zhou; Yong Zhang; Yuanshan Cui
Journal:  Int Neurourol J       Date:  2020-12-31       Impact factor: 2.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.